Methylated Septin9 DNA has been associated with the occurrence of CRC, in plasma obtained from whole-blood specimens. It is indicated for use in average-risk patients who have chosen not to undergo other screening methods, such as colonoscopy or stool-based tests. Methylated Septin 9 is a DNA marker associated with colorectal cancer.